



Pathology Blocks/Slides for consultation: Patient Communication



Released



Seen

Results

Pathology Blocks/Slides for consultation (Order: 82735718)

Pathology Blocks/Slides for consultation: S24-01616

Order: 82735718

- Status: **Final result**
- Visible to patient: **Yes (seen)**
- Next appt: **16/10/2024 at 08:00 AM in Oncology (ACC Infusion Bed 12)**
- Dx: **Malignant neoplasm of overlapping sit...**
- **0 Result Notes**

Component

Case Report

SURGICAL PATHOLOGY
01616

Case: S24-

Authorizing Provider: **Naji Said El-Saghir,**
MD Collected: 07/02/2024 11:21

Ordering Location: **NKBCI**

Clinics Received: 07/02/2024
16:46

Pathologist: **Sara Sinno,**
MD

Specimen: **Breast,**
Left

Diagnosis

**LEFT BREAST, CORE BIOPSY, SUBMITTED BLOCK "P24-2466/1A":
INVASIVE DUCTAL CARCINOMA, GRADE 3/3.**

Electronically signed by Sara Sinno, MD on 12/02/2024 at 16:08



Comment

- Tubule formation: 3/3.
- Nuclear pleomorphism: 3/3.
- Mitosis: 3/3.

Synoptic Checklist

Breast Biomarker Reporting Template

Protocol posted: 22/03/2023

BREAST: BIOMARKER REPORTING TEMPLATE - All Specimens

Test(s) Performed

Estrogen Receptor (ER) Status	Low Positive (1-10% of cells with nuclear positivity)
Percentage of Cells with Nuclear Positivity	3 %
Average Intensity of Staining	Weak
Test Type	Food and Drug Administration (FDA) cleared (test / vendor): Leica
Primary Antibody	6F11

Test(s) Performed

Progesterone Receptor (PgR) Status	Negative (less than 1%)
	Internal control cells present and stain as expected
Test Type	Food and Drug Administration (FDA) cleared (test / vendor): Leica
Primary Antibody	16

Test(s) Performed

HER2 by Immunohistochemistry	Positive (Score 3+)
Percentage of Cells with Uniform Intense Complete Membrane Staining	100 %
Test Type	Food and Drug Administration (FDA) cleared (test / vendor): Ventana
Primary Antibody	4B5

Test(s) Performed	Ki-67
Ki-67 Percentage of Positive Nuclei	70 %
Primary Antibody	MIB1
Cold Ischemia and Fixation Times	Meet requirements specified in latest version of the ASCO / CAP Guidelines

METHODS

Fixative	Formalin
Image Analysis	Not performed



Disclaimer

ER, PR and HER-2/neu, scoring is based on the following algorithm from the 2018 ASCO/CAP guidelines:

ER and PR are considered positive when positive tumor cell nuclei of any intensity are present in >1% of tumor cells.

Her-2/neu IHC scoring is based on the following algorithm from the 2018 ASCO/CAP guidelines: 3+ for circumferential membrane staining that is complete and intense in >10% of invasive tumor cells, 2+ for weak to moderate complete membrane staining observed in >10% of tumor cells or unusual patterns of staining (moderate to intense basolateral staining or intense circumferential staining but heterogeneously within ≤10% of tumor cells), 1+ for incomplete membrane staining that is faint/barely perceptible and within >10% of the invasive tumor cells, and 0 in the absence of staining or for membrane staining that is incomplete and is faint/barely perceptible and within ≤10% of invasive tumor cells.



Gross Description

Received is one block labeled "P24-2466/1A", from INP with a corresponding pathology report dated 26/01/2024 and signed by Dr. Georges Aftimos.

Specimen	Last Resulted: 12/02/24
Collected: 07/02/24	16:08
11:21	

Protocol: [DOCEtaxel / CARBOplatin-HPEvery 21 Days](#)